Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMPACT OF NIRMATRELVIR AND RITONAVIR (PAXLOVID®) ON MORTALITY, PROGRESSION TO SEVERE DISEASE, AND ACTIVITIES OF DAILY LIVING (ADL) WORSENING IN LONG-TERM CARE HOSPITALS (LTCHS) IN KOREA

NCT07089680 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07089680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07089680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMPACT OF NIRMATRELVIR AND RITONAVIR (PAXLOVID®) ON MORTALITY, PROGRESSION TO SEVERE DISEASE, AND ACTIVITIES OF DAILY LIVING (ADL) WORSENING IN LONG-TERM CARE HOSPITALS (LTCHS) IN KOREA
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
September 23, 2025
Completion date
May 29, 2026
Enrollment
937 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019 (covid-19)